ArticleFrontiers in immunology2021
A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Development and validation of a machine learning-driven framework for differentiating pediatric bronchopneumonia from lobar pneumonia: a multicenter investigation.European journal of medical research · 2025Trial
- Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis.Frontiers in immunology · 2026Article
- Development of a machine learning model for early pulmonary tuberculosis diagnosis using blood test biomarkers.BMC infectious diseases · 2025Article
- Fast Screening of Tuberculosis Patients Based on Analysis of Plasma by Infrared Spectroscopy Coupled with Machine Learning Approaches.ACS omega · 2025Article
- Tuberculosis: An Update for the Clinician.Respirology (Carlton, Vic.) · 2025Review
- CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy.Frontiers in immunology · 2025Article
- Plasma ferritin, C-reactive protein, and adenosine deaminase levels in tuberculous lymphadenitis and pleuritis and their role in monitoring treatment response.BMC infectious diseases · 2024Article
- Persistently high plasma procalcitonin levels despite successful treatment of tuberculous pleuritis and tuberculous lymphadenitis patients.Scientific reports · 2024Article
- C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay.Frontiers in immunology · 2024Observational
- Diagnostic performance of host protein signatures as a triage test for active pulmonary TB.Journal of clinical microbiology · 2023Article
- Blood and Site of Disease Inflammatory Profiles Differ in Patients With Pericardial Tuberculosis and Human Immunodeficiency Virus Type 1.Open forum infectious diseases · 2023Article
- Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment.Scientific reports · 2022Article
- Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations.African journal of thoracic and critical care medicine · 2022Review
- Diagnosing Tuberculosis: What Do New Technologies Allow Us to (Not) Do?Respiration; international review of thoracic diseases · 2022Review
- Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis?Frontiers in immunology · 2022Article
- Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results.Pathogens (Basel, Switzerland) · 2021Article
- Candidate Biomarkers to Distinguish Spinal Tuberculosis From Mechanical Back Pain in a Tuberculosis Endemic Setting.Frontiers in immunology · 2021Article
- Combination of HLA-DR onFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.